<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335022">
  <stage>Registered</stage>
  <submitdate>15/01/2010</submitdate>
  <approvaldate>18/01/2010</approvaldate>
  <actrnumber>ACTRN12610000051044</actrnumber>
  <trial_identification>
    <studytitle>An evaluation of the benefits of frequent optimisation using QuickOpt in patients with Cardiac Resynchronisation Therapy Defibrillator Device (CRT-D)</studytitle>
    <scientifictitle>A prospective, randomized, double-blinded, multicentre study to evaluate the benefits of frequent Atrio Ventricular (AV/PV) and Inter-Ventricular (V-V) delay optimisation using QuickOpt in patients with Cardiac Resynchronisation Therapy Defibribrillator (CRT-D) Device.</scientifictitle>
    <utrn />
    <trialacronym>FREEDOM</trialacronym>
    <secondaryid>NCT00418314: Clinicaltrials.gov</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Life-threatening ventricular arrhythmias</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study is aimed at demonstrating that frequent AV/PV and V-V delay optimisation using QuickOpt in patients with Cardiac Resynchronisation Therapy Defibrillation devices results in improved clinical response over standard of care (i.e. empiric programming or one-time optimisation using any non-intracardiac electrogram optimisation methods). SJM has developed  inter-ventricular (V-V) delay optimisation to synchronize the electrical activation of the conducted intrinsic and paced wavefronts between the pacing electrodes. The Atrio-ventricular (AV/PV) optimisation method characterises the inter-atrial conduction patterns in order to maximise preload and allow for proper timing of mitral valve closure. The intervention is observed for a period of 12 months, from which time the device will remain implanted.</interventions>
    <comparator>Empiric programming or optimisation as per sites standard of care for the duration of the study: for example EchoCardioGram (ECHO).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Heart Failure (HF) clinical composite score as defined by Packer: Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure, Journal of Cardiac Failure 2001: 7, 2; 176-182.</outcome>
      <timepoint>Improvement at 12 months over baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause cardiovascular and heart failure mortality: Any cause during the 12month follow up will be collected for all patietns within 2 weeks of the incident - Complete device interrogation, print device data and Adverse Event/hospitalisation Case Report Form (CRF) completion</outcome>
      <timepoint>Up to 12 months post implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause cardiovascular and heart failure hospitalisations: Any cause during the 12month follow up will be collected for all patietns within 2 weeks of the incident - Complete device interrogation, print device data and AE/hospitalisation CRF completed</outcome>
      <timepoint>Up to 12 months post implant.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Patient meets current CRT-D indications and be implanted with a St. Jude Medical (SJM) CRT-D device with V-V timing and a copatible lead system.
- Patient has the ability to complete a 6-minute hall walk with the only limiting factor to be fatigue or shortness of breath
-Patient has the ability to independantly comprehend and complete a Quality Of Life (QOL) questionnaire
- Patient is geographically stable and willing to coply with the required follow up schedule</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Patient has an epicardial ventricular lead system
-patient has the ability to walk greater or equal to 450 meters in 6 meters
- Patient has limited intrinsic atrial activity (&lt;40bpm)
- Patient has persistent or permanent Atrial Fibrillation (AF)
- Patient has a 2 or 3 degree heart block
- Patients life expectancy is less than a year
- Patient is less than 18yrs old
- Patient is pregnant
- Patient is on an Intravenous (IV) inotropic agent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All patients must meet indications to be implanted with a SJM CRT-D device with V-V timing and compatible lead system. The CRT-D must be switched ON prior to performing any baseline measurements at enrollment. Patients must be enrolled withing two weeks post CRT-D implant. 
Randomisation will be blocked by investigational sitet and stratified by the patients cardiomyopathy classification of ischemic or non-ischemic. In order to do so sealed opaque envelopes will be used for the randomisation process</concealment>
    <sequence>Neither the patient nor the physician/nursing staff performing the HF assessment will be aware of the randomisation assignement. Heart Failure Clinical composite Assessement CRF is completed by and signed by a blinded rater only. Randomisation will be done via stratification based upon the patients cardiomyopathy classification of: ischemic or on-ischemic.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>16/08/2007</anticipatedstartdate>
    <actualstartdate>23/10/2006</actualstartdate>
    <anticipatedenddate>3/10/2008</anticipatedenddate>
    <actualenddate>3/10/2008</actualenddate>
    <samplesize>1500</samplesize>
    <actualsamplesize>1652</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA,VIC</recruitmentstate>
    <postcode>2010</postcode>
    <postcode>4001</postcode>
    <postcode>6909</postcode>
    <postcode>2076</postcode>
    <postcode>3076 - Epping</postcode>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St. Jude Medical</primarysponsorname>
    <primarysponsoraddress>St. Jude Medical World Headquarters
One Lellehei Plaza
St. Paul MN 55117</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St. Jude Medical</fundingname>
      <fundingaddress>St. Jude Medical World Headquarters
One Lillehei Plaza
St. Paul MN 55117</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to prospectively evaluate the benefits of frequent AV/PV and V-V delay optimisation using QuickOpt in patients iwth CRT-D devices</summary>
    <trialwebsite />
    <publication>NA</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>390 Victoria Rd
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate />
      <hrec>H06/156</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Uniting Care health Human Research Ethics Committee</ethicname>
      <ethicaddress>PO Box 499
toowong QLD 4066</ethicaddress>
      <ethicapprovaldate>26/04/2007</ethicapprovaldate>
      <hrec>2007/16</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Northern Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>185 Cooper St
Epping VIC 3076</ethicaddress>
      <ethicapprovaldate>30/03/2007</ethicapprovaldate>
      <hrec>10/07/2010</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hollywood Private Hopsital Human Research Ethics Committee</ethicname>
      <ethicaddress>Monash Avenue
Nedlands WA 6909</ethicaddress>
      <ethicapprovaldate>15/08/2007</ethicapprovaldate>
      <hrec>HPA235</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Lisa Guzzo</name>
      <address>Clinical Projects Leader
Leonardo Da Vincilaan 11, Box F1
Zaventem 1935</address>
      <phone>+322 774 6856</phone>
      <fax>+322 774 6946</fax>
      <email>lguzzo@sjm.com</email>
      <country>Belgium</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Lisa Guzzo</name>
      <address>Clinical Projects Leader
Leonardo Da Vincillaan 11, Box F1
Zaventem 1935</address>
      <phone>+322 774 6856</phone>
      <fax>+322 774 6946</fax>
      <email>lguzzo@sjm.com</email>
      <country>Belgium</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jessica Andrews</name>
      <address>St Jude Medical Australia
17 Orion Rd
Lane Cove NSW 2066</address>
      <phone>+612 9936 1236</phone>
      <fax>+612 9936 1222</fax>
      <email>jandrews04@sjm.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Gras</name>
      <address>Nouvelles Cliniques Nantaises</address>
      <phone>+0033228255115</phone>
      <fax />
      <email>dgras@ncn.fr</email>
      <country>France</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>